Auris Medical Holding Ltd. logo
Auris Medical Holding Ltd. EARS

Auris Medical Holding Ltd. Net Income | EARS

Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.

Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]

It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.

The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.

Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.

It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.

However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.

Annual Net Income Auris Medical Holding Ltd.

2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
-8.2 M -6.63 M -11.5 M -24.4 M -30.7 M -29.7 M -18.2 M -15 M -4.6 M -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
-4.6 M -30.7 M -16.5 M

References

  1. Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.

Net Income of other stocks in the Biotechnology industry

Issuer Net Income Price % 24h Market Cap Country
Dicerna Pharmaceuticals, Inc. Dicerna Pharmaceuticals, Inc.
DRNA
-113 M - 0.34 % $ 2.98 B usaUSA
ERYTECH Pharma S.A. ERYTECH Pharma S.A.
ERYP
-228 K - 1.3 % $ 27.7 M franceFrance
GW Pharmaceuticals plc GW Pharmaceuticals plc
GWPH
-58.1 M - - $ 6.81 B britainBritain
Kadmon Holdings, Inc. Kadmon Holdings, Inc.
KDMN
-109 M - - $ 1.7 B usaUSA
Liminal BioSciences Liminal BioSciences
LMNL
622 K - - $ 256 M canadaCanada
Neos Therapeutics, Inc. Neos Therapeutics, Inc.
NEOS
-16.9 M - -2.54 % $ 57.2 M usaUSA
Odonate Therapeutics, Inc. Odonate Therapeutics, Inc.
ODT
-126 M - -3.18 % $ 58.5 M usaUSA
Orphazyme A/S Orphazyme A/S
ORPH
-633 M - -2.25 % $ 31.3 M danmarkDanmark
Osmotica Pharmaceuticals plc Osmotica Pharmaceuticals plc
OSMT
-79.6 M - -10.74 % $ 89.9 M usaUSA
Pandion Therapeutics, Inc. Pandion Therapeutics, Inc.
PAND
-38.1 M - - $ 1.77 B usaUSA
Translate Bio, Inc. Translate Bio, Inc.
TBIO
-53.8 M - - $ 2.81 B usaUSA
Trillium Therapeutics Inc. Trillium Therapeutics Inc.
TRIL
-59.3 M - - $ 1.94 B canadaCanada
Urovant Sciences Ltd. Urovant Sciences Ltd.
UROV
-147 M - - $ 532 M britainBritain
Acceleron Pharma Inc. Acceleron Pharma Inc.
XLRN
-125 M - - $ 10.9 B usaUSA
Zealand Pharma A/S Zealand Pharma A/S
ZEAL
-1.02 B - 0.52 % $ 821 M danmarkDanmark
Zogenix, Inc. Zogenix, Inc.
ZGNX
-209 M - -4.97 % $ 664 M usaUSA
Yunhong International Yunhong International
ZGYH
-797 K - 0.10 % $ 92.2 M chinaChina
ZIOPHARM Oncology, Inc. ZIOPHARM Oncology, Inc.
ZIOP
-80 M - -7.58 % $ 264 M usaUSA
Leap Therapeutics Leap Therapeutics
LPTX
5 M - 368.57 % $ 41.9 M usaUSA
Cortexyme Cortexyme
CRTX
-84 M - -1.05 % $ 67.1 M usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
-1.36 M - - $ 5.72 M chinaChina
FSD Pharma FSD Pharma
HUGE
-27 M - 5743.5 % $ 69.7 M canadaCanada
BioAtla BioAtla
BCAB
-59.6 M $ 1.74 0.64 % $ 102 M usaUSA
Catalyst Pharmaceuticals Catalyst Pharmaceuticals
CPRX
214 M - - $ 3.85 B usaUSA
ARCA biopharma ARCA biopharma
ABIO
-105 M - 1052.0 % $ 415 M usaUSA
Acasti Pharma Acasti Pharma
ACST
-7.79 M - 4.01 % $ 150 M canadaCanada
ADiTx Therapeutics ADiTx Therapeutics
ADTX
-43.1 M - - $ 374 usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
-10.4 M - 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
-19.2 M - -10.17 % $ 12.2 K usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
-155 M - - $ 1.01 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
-22.4 M - 1.93 % $ 17.4 M usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
-49.9 M - 10.36 % $ 9.8 M usaUSA
AlloVir AlloVir
ALVR
-43.4 M - 4.14 % $ 49.1 M usaUSA
Apellis Pharmaceuticals Apellis Pharmaceuticals
APLS
22.4 M - - $ 5.18 B usaUSA
Athira Pharma Athira Pharma
ATHA
-106 M - - $ 269 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
-2.91 M - -52.27 % $ 4.45 M usaUSA
AVROBIO AVROBIO
AVRO
-74.2 B - 1083.1 % $ 745 M usaUSA
AstraZeneca PLC AstraZeneca PLC
AZN
10.2 B - - $ 96.9 B britainBritain
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
-10.3 M - -2.5 % $ 5.88 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
287 M - 0.49 % $ 251 B cayman-islandsCayman-islands
Bio-Path Holdings Bio-Path Holdings
BPTH
-9.89 M - - $ 100 K usaUSA
Cara Therapeutics Cara Therapeutics
CARA
-18.2 M - -3.03 % $ 260 M usaUSA
ChromaDex Corporation ChromaDex Corporation
CDXC
17.4 M - -0.88 % $ 598 M usaUSA
Caladrius Biosciences Caladrius Biosciences
CLBS
-16.6 M - -16.75 % $ 25.8 M usaUSA
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCC
3 M - -5.98 % $ 34.1 M usaUSA
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
3 M - -4.36 % $ 27 M usaUSA
Diffusion Pharmaceuticals Diffusion Pharmaceuticals
DFFN
-27 M - 11.68 % $ 8.97 M usaUSA
Eloxx Pharmaceuticals Eloxx Pharmaceuticals
ELOX
-3.75 M - -5.68 % $ 8.28 M usaUSA
Enochian Biosciences Enochian Biosciences
ENOB
-178 M - - $ 40.5 M usaUSA